Company profile: CytomX Therapeutics
1.1 - Company Overview
Company description
- Provider of proteolytically activated Probody therapeutics designed to activate only in cancer via tumor-specific proteases, minimizing activity in healthy tissue. Pipeline includes CX-904, a T-cell-engaging bispecific Probody targeting EGFR and CD3 in Phase 1 for advanced solid tumors; CX-2051, a conditionally activated EpCAM-targeting antibody-drug conjugate; and CX-801, an interferon alpha-2b Probody.
Products and services
- CX-2051: Conditionally activated antibody-drug conjugate targeting EpCAM for epithelial cancers, engineered to deliver systemic treatment while limiting exposure to normal tissues
- CX-904: Clinical-stage T-cell-engaging bispecific Probody targeting EGFR on cancer cells and CD3 on T cells, under Phase 1 trials for advanced solid tumors
- Probody Therapeutics: Proteolytically-activated antibodies that employ tumor-specific proteases to remove a masking peptide, enabling precise target binding while minimizing activity in healthy tissues
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to CytomX Therapeutics
Xoft
HQ: United States
Website
- Description: Provider of electronic brachytherapy (eBx) systems for radiation oncology, including the Elekta Xoft Axxent system with miniaturized X-ray source, Axxent Controller, SPX Controller for surface treatments, Axxent X-ray Source, balloon and extended balloon applicators for intracavitary and intraoperative therapy, and Radion Hub Peer Review cloud software for network-wide peer review to improve patient safety and quality care.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Xoft company profile →
Koya Medical
HQ: United States
Website
- Description: Provider of breakthrough treatments for lymphedema and venous diseases, as a transformative healthcare company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Koya Medical company profile →
Cleveland Diagnostics
HQ: United States
Website
- Description: Provider of efficacious, affordable cancer diagnostic tests, including IsoPSA, a blood test designed to improve the accuracy of prostate cancer detection and reduce unnecessary biopsies by distinguishing cancer-related PSA proteins, and the Solvent Interaction Analysis Platform, which measures structural differences in proteins to identify cancer biomarkers and facilitate development of blood tests for cancer diagnostics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cleveland Diagnostics company profile →
Neogene Therapeutics
HQ: The Netherlands
Website
- Description: Provider of T cell therapies targeting cancer neo-antigens, developing technologies to engineer designer T cells with optimized neo-antigen specificities to seek and destroy cancer cells. Offers engineered TCR therapies for solid tumors, including a TP53 R175H-targeting TCR therapy currently in Phase I trials in the US.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Neogene Therapeutics company profile →
ScandiDos
HQ: Sweden
Website
- Description: Provider of a unique measurement system for radiation therapy in cancer treatment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ScandiDos company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for CytomX Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to CytomX Therapeutics
2.2 - Growth funds investing in similar companies to CytomX Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for CytomX Therapeutics
4.2 - Public trading comparable groups for CytomX Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →